Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab*

Vaheh Oganesyan1, Li Peng, Robert M. Woods, Herren Wu, and William F. Dall’Acqua2

From the Department of Antibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, Maryland 20878

Received for publication, March 13, 2015, and in revised form, April 17, 2015 Published, JBC Papers in Press, April 29, 2015, DOI 10.1074/jbc.M115.652156

We report the three-dimensional structure of human interferon-α2A (IFN-α2A) bound to the Fab fragment of a therapeutic monoclonal antibody (sifalimumab; IgG1/κ). The structure of the corresponding complex was solved at a resolution of 3.0 Å using molecular replacement and constitutes the first reported structure of a human type I IFN bound to a therapeutic antibody. This study revealed the major contribution made by the first complementarity-determining region in each of sifalimumab light and heavy chains. These data also provided the molecular basis for sifalimumab mechanism of action. We propose that its interferon-neutralizing properties are the result of direct competition for IFN-α2A binding to the IFN receptor subunit 1 and not IFN receptor subunit 2.

Background: We investigated the molecular basis of human IFN-α2A recognition by sifalimumab.

Results: We determined the structure of the complex between the Fab of sifalimumab and IFN-α2A.

Conclusion: The interferon-neutralizing properties of sifalimumab result from direct competition for IFN-α2A binding to IFN receptor subunit 1 and not IFN receptor subunit 2.

Significance: These data provide the basis for the mechanism of action of sifalimumab.

Interferons (IFNs) belong to the “4-helical cytokines” superfamily (1) and can be grouped into types I, II, and III. IFN-γ and IFN-λ are the only known members of the type II and III IFNs, respectively (2, 3), whereas type I IFNs constitute a family of cytokines expressed from more than 15 genes. Most notably, these include IFN-α, IFN-β, IFN-τ, IFN-κ, IFN-ε, IFN-δ and IFN-ω. The critical role of IFNs in modulating the host mammalian responses to infections has been well documented (4–6). More recently, IFNs have also been shown to be key immunoregulatory cytokines. As such, they play a central role in the onset of various autoimmune diseases (7, 8). Direct evidence includes the observation that autoimmune-predisposed mice deficient in the IFN-α/β receptor exhibit significantly reduced disease manifestations such as the presence of antineutrophil cytoplasmic antibodies, hemolytic anemia, anti-DNA autoantibodies, and kidney disease (9). In particular, systemic lupus erythematosus, type I diabetes, and Sjögren syndrome, as well as thyroid diseases, have now been linked to the action of IFN-α (10). The existence of at least 13 subtypes within the IFN-α family (11) further complicates a thorough understanding of these pathways. To contribute to the treatment of autoimmune diseases, AstraZeneca/MedImmune has developed sifalimumab, a fully human monoclonal antibody that binds to, and inhibits the actions of multiple IFN-α subtypes.

We sought to understand the molecular basis of human IFN-α2A recognition by sifalimumab. For this purpose, we solved the x-ray crystal structure of the complex between the Fab fragment of this antibody and IFN-α2A. The structures of several type I human IFNs (e.g. IFN-α2A, IFN-α2B, and IFN-β), unbound or bound to a single chain Fv (scFv), have already been determined using either x-ray crystallography or nuclear magnetic resonance (NMR) (12–16). However, this study describes the first three-dimensional structure of a human type I IFN bound to a therapeutic antibody currently in human. Our data permitted us to describe in detail the corresponding interface and provide a molecular understanding the interferon-neutralizing properties of sifalimumab.

Experimental Procedures

Reagents, Conventions, and Illustrations—All chemicals employed were of analytical grade. The histidine-tagged recombinant extracellular domain of the IFN-α receptor 1 (IFNAR1-His6) was a generous gift from Sandrina Phipps (MedImmune). All antibody and antigen amino acid positions mentioned in the text were identified according to a consecutive numbering scheme. In these conditions, the Kabat-defined complementarity determining regions (CDR)3 (17) of sifalimumab were identified as follows: 31–35, 51–57, and 90 –98 for the light chain and 50 – 66, and 98 –105 for the heavy chain (CDR1, H2 and H3, respectively), and 24 –35, 51–57, and 90 –98 for the light chain (CDR1, L2 and L3, respectively). All illustrations were prepared using PyMOL (DeLano Scientific, Palo Alto, CA).

THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 290, NO. 24, pp. 14979 –14985, June 12, 2015 © 2015 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.

Author’s Choice

*This work was supported by AstraZeneca. All authors are full-time employees of MedImmune LLC (Gaithersburg, MD).

1 To whom correspondence may be addressed. Tel.: 301-398-5851; Fax: 301-398-9851; E-mail: oganesyanv@medimmune.com.

2 To whom correspondence may be addressed. Tel.: 301-398-4536; Fax: 301-398-9536; E-mail: dallacquaw@medimmune.com.

3 The abbreviations used are: CDR, complementarity-determining regions; PDB, Protein Data Bank; r.m.s., root mean square; LC, light chain; HC, heavy chain.
**Table 1**

| Sifalimumab Fab/IFN-α2A model refinement statistics |
|---------------------------------------------------|
| Resolution limits (Å)                               | 20.0–3.0 |
| R factor (free r factor)                            | 0.206 (0.272) |
| R.m.s. deviation bonds (Å)                          | 0.011 |
| R.m.s. deviation angles (Å)                         | 1.38 |
| Residues in most favored region of (φ,ψ) space (%) | 89.5 |
| Residues in additionally allowed region of (φ,ψ) space (%) | 10.0 |
| Residues in generously allowed region of (φ,ψ) space (%) | 0.5 |
| Number of protein atoms                             | 9166 |
| Number of non-protein atoms                         | 53 |
| Mean B factor (Model/Wilson), Å²                    | 67/70 |

*The Ramachandran plot was produced using PROCHECK (45).*

**Protein Expression, Purification, Crystallization, and X-ray Data Collection**—Detailed purification, crystallization, and data collection procedures have been previously described (18). In short, crystals of the sifalimumab Fab/IFN-α2A complex diffracting to 3.0 Å were obtained using vapor diffusion. The orthorhombic crystals belonged to the I222 space group with unit cell parameters a = 134.82, b = 153.26, c = 163.49 Å. The crystals exhibited a relatively loose packing with a solvent content of 59.3% and 3.02 Å³ Da⁻¹, respectively. Two sifalimumab Fab/IFN-α2A complexes were in the asymmetric part of the unit cell.

**Structure Determination and Refinement**—Diffraction images were integrated and scaled using HKL 2000 (19). Molecular replacement, refinement, and electron density calculation were completed via the CCP4 (Collaborative Computational Project Number 4) program suite (20). The crystal structure of the sifalimumab Fab/IFN-α2A complex was solved using molecular replacement and refined at 3.0-Å resolution. The search model for sifalimumab Fab consisted of the Fab portion of another antibody from AstraZeneca/MedImmune whose structure was determined at 2.17-Å resolution (21). The sequence identities between the Fab portions of sifalimumab and the search model were 95.3 and 78.6% for the light and heavy chains, respectively. The non-identical amino acids were first modeled as alanine precisely, sifalimumab light chain was divided into sections corresponding to residues 1–40, 41–106, 107–177, and 178–215. Likewise, the sifalimumab heavy chain was divided into sections corresponding to residues 1–62, 63–129, 130–185, and 186–219. Finally, IFN-α2A was divided into sections corresponding to residues 1–20, 21–51, 52–113, and 114–157. The same portions were used for NCS restraints application. As we previously described (18), the IFN-α2A antigen used in this study included one extra threonine and one extra serine residue on its N-terminal end (numbered as 1 and 0, respectively). Amino acids −1, 0, and 1, along with Nε2 of His-7, were found to coordinate a total of 2 Ni²⁺ ions (first and third). Another two Ni²⁺ ions (second and fourth) were coordinated by His-190 in the sifalimumab light chain. The fifth and sixth Ni²⁺ ions did not have histidine residues in the coordination sphere. Ni²⁺ ions were the only divalent metal ions present in the crystallization mixture, and could be identified by their fit to the corresponding electron density.

**Analysis of Sifalimumab Binding to IFN-α2A**—The interaction of immobilized IFN-α2A with sifalimumab was monitored using a KinExA 3000 instrument (Sapidyne Instruments, Boise, ID). IFN-α2A was first coated onto UltraLink Biosupport beads (Pierce, Rockford, IL) at concentrations of 5 and 10 µg/ml in 0.05 M NaHCO₃, pH 9.0, overnight at 4 °C according to the manufacturer’s instructions. Coated beads were then separated from unreacted IFN-α2A using a KinExA Pro 1.0.3 software. The dissociation constant (KD) was determined by fitting the individual equilibrium titration data to a 1:1 binding model using the KinExA Pro 1.0.3 software.
Receptor-ligand Competition by Sifalimumab—The ability of sifalimumab to inhibit the human IFNAR1/IFN-α2A and IFNAR2/IFN-α2A interactions was monitored using a ProteOn XPR36 instrument (Bio-Rad). The extracellular domain of IFNAR1 (MedImmune) was immobilized to the EDAC/Sulfo-NHS-activated surface of a GLC biosensor chip (Bio-Rad) using standard amine coupling (200 nM in 10 mM sodium acetate buffer, pH 5.0) at a density of ~4,800 resonance units according to the manufacturer’s instructions. The extracellular domain of IFNAR2 (MedImmune) was also immobilized using standard amine coupling (50 nM in 10 mM sodium acetate buffer, pH 4.0) at a density of ~2,000 resonance units. IFN-α2A and sifalimumab were prepared in PBS, pH 7.4, containing 0.005% Tween 20. Sifalimumab competition was assessed by 2 consecutive injections of IFN-α2A and a mixture of IFN-α2A and sifalimumab over the IFNAR1 or IFNAR2 surfaces. For IFNAR1, IFN-α2A was first injected at 200 μg/ml (30 μl/min for 120 s), which was followed by a second injection (30 μl/min for 120 s) of the IFN-α2A (200 μg/ml)/sifalimumab (100 μg/ml) mixture. For IFNAR2, IFN-α2A was first injected at 10 μg/ml (30 μl/min for 120 s), which was followed by a second injection (30 μl/min for 120 s) of the IFN-α2A (10 μg/ml)/sifalimumab (100 μg/ml) mixture. The extent of competition was derived from the additional binding detected from the second injection. All sensogram data were processed by ProteOn Manager 3.1 software (Bio-Rad), and the binding graphs were prepared with Prism (GraphPad).

Results and Discussion

Sifalimumab Fab/IFN-α2A Three-dimensional Structure—We successfully determined the x-ray crystal structure of the complex between the Fab of an anti-human IFN-α therapeutic antibody (sifalimumab) and IFN-α2A. The corresponding refinement statistics are given in Table 1. Two sifalimumab Fab fragments in the asymmetric unit superimposed with an r.m.s. deviation of 0.31 Å (maximum displacement of 1.3 Å was for Ca/136 in the heavy chain and 1.2 Å for Ca/204 in the light chain). This value is well within the estimated overall coordinate error value of 0.34 Å. In addition, the elbow angles were calculated for both molecules as described (29) and separately estimated at 170.9° and 172.5°. These values are again well within the significance limit of 2–3° (29). Thus, we concluded that the 2 sifalimumab Fab molecules in the asymmetric unit were essentially identical. Both antigen molecules (IFN-α2A) exhibited a r.m.s. deviation of 0.6 Å when superimposed. However, the greatest differences occurred away from the Fab/IFN-α2A interface, and close to the IFN-α2A C-terminal region.
(maximum displacement of 3 Å was for C\textsubscript{H9251}/156). As with sifalimumab Fab, both antigen molecules in the asymmetric unit could be considered essentially identical. Therefore, all subsequent descriptions of the antibody/antigen interface were made using 1 of the 2 complexes (namely chains A, B, and C in our PDB ID 4YPG).

The interface contributed by the sifalimumab Fab portion could best be described as a canyon, whereas IFN-\alpha\textsubscript{2A} exhibited a remarkable shape complementarity to this groove as indicated in Fig. 1\textbf{A}. A shape complementarity of 0.674 between sifalimumab Fab and IFN-\alpha\textsubscript{2A} was calculated using the “sc” program from the CCP4 suite (Collaborative Computational Project Number 4) (20). This represents a very high degree of complementarity between both partners. For comparison purposes, the shape complementarity between sifalimumab Fab heavy and light chains was estimated at 0.669. The charge complementarity between sifalimumab Fab and IFN-\alpha\textsubscript{2A} is provided in Fig. 1, \textbf{B} and \textbf{C}. The basic surfaces of both variable regions of the antibody exhibited very good complementarity to the acidic surface of the antigen. Finally, we also noted that the side of the antigen of the sifalimumab Fab/IFN-\alpha\textsubscript{2A} contact interface was formed mainly by parts of B (residues 49–69), C (residues 78–101), and D (residues 112–133) helices as illustrated in Fig. 1\textbf{D}.

The buried surface area upon formation of the complex between sifalimumab Fab and IFN-\alpha\textsubscript{2A} was estimated at more than 1,300 Å\textsuperscript{2} (as calculated from the PISA server). The contact interface included 20 amino acids from each of the antibody polypeptides and ~40 amino acids from the antigen. In particular, the heavy and light chains of sifalimumab Fab covered ~600 and 700 Å\textsuperscript{2} of solvent-accessible area upon complex formation, respectively. The list of all hydrogen bonds between both chains of sifalimumab Fab and IFN-\alpha\textsubscript{2A} can be found in Table 2. It is worth noting that the heavy and light chain CDRs of sifalimumab Fab contributed unequally to the interaction with IFN-\alpha\textsubscript{2A}. Indeed, 4 intermolecular hydrogen bonds involved the heavy chain first CDR (CDRH1, Fig. 2\textbf{A} and Table 2), whereas 9 intermolecular hydrogen bonds involved the light chain first CDR (CDRL1; Fig. 2\textbf{B} and Table 2). Asn-55/N\textsubscript{H9254} in the second CDR of the sifalimumab Fab heavy chain (CDRH2) made a lone hydrogen bond with IFN-\alpha\textsubscript{2A} Asp-2/O\textsubscript{H9254} (Fig. 2\textbf{C}).

\begin{table}[h]
\centering
\caption{Affinity measurement for the binding of sifalimumab to IFN-\alpha\textsubscript{2A}}
The dissociation constant ($K\textsubscript{D}$) was determined using a KinExa instrument as described under “Experimental Procedures.”
\begin{tabular}{lcc}
\hline
Molecule & $K\textsubscript{D}$ & 95\% confidence interval$^a$ \\
\hline
Sifalimumab & 44 & 27–65 \\
\hline
\end{tabular}
\footnote{$^a$ The 95\% confidence interval indicated the range over which the measured $K\textsubscript{D}$ is thought to vary due to the reproducibility of the instrument. The residual error between the fitted and theoretical curves was 2.7\%.}
\end{table}

\section*{FIGURE 2. Representations of the intermolecular contacts between IFN-\alpha\textsubscript{2A} and sifalimumab around heavy chain CDR1 (A), light chain CDR1 (B), heavy chain CDR2 (C), light chain CDR2 (D), and heavy (blue) and light (green) chains CDR3 (E). In all panels, the antigen is shown in red. Sifalimumab residues were numbered consecutively. Dotted lines represent hydrogen bonds.}
The contribution of the second CDR of the sifalimumab Fab light chain (CDRL2) for binding to IFN-α2A appeared somewhat less specific, in that all corresponding intermolecular hydrogen bonds only involved the main chain CDRL2 atoms of Gly-51 and Arg-55 (Fig. 2D and Table 2). Finally, the spatially close CDRH3 and CDRL3 of the sifalimumab Fab created 2 intermolecular hydrogen bonds each with the antigen (Fig. 2E and Table 2). In CDRL3, Tyr-92/Ω and Arg-97/Ν were involved in hydrogen bonds with IFN-α2A Glu-61/Ne2 and Glu-96/Oe1, respectively. CDRH3 was only involved in contacts with IFN-α2A Glu-96/Oe1,2 through its main chain Ile-101/N atom. Interestingly, 2 intermolecular hydrogen bonds were mediated by one residue in the second framework of the sifalimumab light chain (Tyr-50). In summary, sifalimumab CDRL1 and CDRH1 made the largest contribution to formation of the high affinity complex between IFN-α2A and sifalimumab ($K_d$ shown in Table 3). Importantly, none of the side chains in sifalimumab CDRL2 and CDRH3 were involved in hydrogen bonds with IFN-α2A.

Radhakrishnan et al. (12) observed that human IFN-α2B (99% identical to human IFN-α2A due to one amino acid difference, namely K23R) can form Zn$^{2+}$ ion-mediated homodimers. Our model did not indicate such a dimerization mechanism because no ions were found to be shared between 2 contacting IFN-α2A molecules (despite the presence of Ni$^{2+}$ in the crystallization mixture). This comforts the notion that the active form of IFN-α molecules is monomeric, as determined by Klaus et al. (13).

Implications for Sifalimumab Mechanism of Action—The type I IFN receptor (shared by all human type I IFNs) comprises 2 major transmembrane subunits, namely IFNAR1 and IFNAR2 (30–31). IFN-α binds to IFNAR2 with a much faster $k_{on}$ and slower $k_{off}$ than those measured for IFNAR1 (32, 33). Therefore, a two-step assembling mechanism was proposed for formation of the tertiary IFN signal complex, in which IFN-α first binds IFNAR2 and then recruits IFNAR1 (32, 34). The present study provides important clues related to sifalimumab mechanism of action.

A number of studies have revealed critical residues on both IFNAR2 and IFN-α2 through mutagenesis, NMR, and x-ray crystallography (35–40). As can be observed when superimposing the x-ray structure of the human IFN-α2A-IFNAR1-IFNAR2 ternary complex (PDB ID 3SE3) (40) with the sifalimumab-IFN-α2A complex (Fig. 3), both sifalimumab and human IFNAR2 bind to opposite sides of the IFN molecule. In addition, various human IFN-α2 residues identified by Piehler et al. (37) as critical for binding to IFNAR2 (namely Leu-30, Arg-33, Arg-144, Ala-145, Met-148, and Arg-149) were also found to be on the opposite side of the sifalimumab binding site (Fig. 3). These data agree with the observation that sifalimumab can bind to IFN-α2A-IFNAR2 complexes (Fig. 4A), and, thus, rule out a mechanism of action in which the antibody interferes with the corresponding receptor/ligand interaction.

Interestingly, binding of sifalimumab to IFN-α2A-IFNAR1 complexes could not be detected (Fig. 4B). In fact, sifalimumab actually inhibited the binding of IFN-α2A to immobilized IFNAR1, as observed from the drop in signal upon injection of the IFN-α2A/sifalimumab mixture. Indeed, the interaction of sifalimumab/IFN-α2A ($K_d$ of 44 pm) is much stronger than that of IFNAR1/IFN-α2A ($K_d$ of 1.5 μM (33)). Therefore, sifalimumab interferon blocking activity appears to be caused by inhibition of IFN-α2 binding to IFNAR1. Our structure of the sifalimumab Fab-IFN-α2A complex provided a better understanding of this phenomenon. In particular, crucial amino acids
coherent model of the mechanism of action for sifalimumab

The x-ray structure of the human IFN-α2A

region defined by these amino acids showed a significant overlap.

lectively, these data suggest that sifalimumab precludes the

Fab/IFN-α2A competitive inhibitor of the IFN-α2B complex.

In summary, we conclude that sifalimumab acts as a direct

steric hindrance.

for the IFN-α2/IFNAR1 interaction have been identified (33,

41–43), such as Asn-65, Glu-78, Leu-80, Tyr-85, Tyr-89, Ile-100, and Arg-120 in IFN-α2 B, C, and D helices. When mapped onto the structure of the sifalimumab-IFN-α2A complex, the region defined by these amino acids showed a significant overlap with the sifalimumab binding site (Fig. 5). Moreover, when the x-ray structure of the human IFN-α2:IFNAR1:IFNAR2 ternary complex (PDB ID number 3SE3) (40) was superimposed with that of the sifalimumab-IFN-α2A complex (Fig. 3), it clearly appears that a large overlap exists between sifalimumab Fab/IFN-α2A and IFN-α2/IFNAR1 contacting surfaces. Collectively, these data suggest that sifalimumab precludes the IFN-α2/IFNAR1 interaction through direct steric hindrance.

In summary, we conclude that sifalimumab acts as a direct competitive inhibitor of the IFN-α2/IFNAR1 interaction. A coherent model of the mechanism of action for sifalimumab thus emerges, and indicates the antibody does not interfere with the first step in the response to IFN-α2, namely the ligand:IFNAR2 complex formation. Rather, we suggest that sifalimumab sterically interferes with the recruitment of IFNAR1 and prevents formation of the IFN-α2:IFNAR1:IFNAR2 ternary complex.

Acknowledgment—We thank Michael A. Nissen, ELS, of AstraZeneca (Gaithersburg, MD), for assistance in editing and formatting the manuscript for submission.

References

1. Hill, E. E., Morea, V., and Chothia, C. (2002) Sequence conservation in families whose members have little or no sequence similarity: the four-helical cytokines and cytochromes. J. Mol. Biol. 322, 205–233
2. Pestka, S., Krause, C. D., and Walter, M. R. (2004) Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202, 8–32
3. Donnelly, R. P., and Kotenko, S. V. (2010) Interferon-α: a new addition to an old family. J. Interferon Cytokine Res. 30, 555–564
4. Isaacs, A., and Lindenmann, J. (1957) Virus interference. J. Interferon Res. 7, 429–438
5. Gresser, I., Tovey, M. G., Bandu, M. E., Maury, C., and Brouty-Boyé, D. (1976) Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum: I. Rapid evolution of encephalomyocarditis virus infection. J. Exp. Med. 144, 1305–1315
6. Alsharifi, M., Müllbacher, A., and Regner, M. (2008) Interferon type I responses in primary and secondary infections. Immunol. Cell Biol. 86, 239–245
7. Baccala, R., Kono, D. H., and Theofilopoulos, A. N. (2005) Interferons as pathogenic effectors in autoimmunity. Immunol. Rev. 204, 9–26
8. Theofilopoulos, A. N., Baccala, R., Beutler, B., and Kono, D. H. (2005) Type I interferons (α/β) in immunity and autoimmunity. Annu. Rev. Immunol. 23, 307–336
9. Santiago-Raber, M. L., Baccala, R., Haraldsson, K. M., Choube, D., Stewart, T. A., Kono, D. H., and Theofilopoulos, A. N. (2003) Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197, 777–788
10. Selmi, C., Lleo, A., Zuin, M., Podda, M., Rossaro, L., and Gershwin, M. E. (2006) Interferon-α and its contribution to autoimmunity. Curr. Opin. Investig. Drugs 7, 451–456
11. Foster, G. R., and Finter, N. B. (1998) Are all type I human interferons equivalent? J. Viral Hepat. 5, 143–152
12. Radakrishnan, R., Walter, L. J., Hruza, A., Reichert, P., Totta, P. P., Nagabhushan, T. L., and Walter, M. R. (1996) Zinc mediated dimer of human interferon-α2b revealed by X-ray crystallography. Structure 4, 1453–1463
13. Klaus, W., Gsell, B., Labhardt, A. M., Wipf, B., and Senh, H. (1997) The three-dimensional high resolution structure of human interferon α-2a determined by heteronuclear NMR spectroscopy in solution. J. Mol. Biol. 274, 661–675
14. Karpusas, M., Nolte, M., Benton, C. B., Meier, W., Lipscomb, W. N., and Goelz, S. (1997) The crystal structure of human interferon β at 2.2 Å resolution. Proc. Natl. Acad. Sci. U.S.A. 94, 11813–11818
15. Ouyang, S., Gong, B., Li, J. Z., Zhao, L. X., Wu, W., Zhang, F. S., Sun, L., Wang, S. J., Pan, M., Li, C., Liang, W., Shaw, N., Zheng, J., Zhao, G. P., Wang, Y., Liu, Z. J., and Liang, M. (2012) Structural insights into a human anti-IFN antibody exerting therapeutic potential for systemic lupus erythematosus. J. Mol. Med. (Berl.) 90, 837–846
16. Ghassiani, H., Belcourt, P. J., Sauer, S., Hodgson, D. J., Brochu, D., Gilbert, M., and Aubin, Y. (2013) A single N-acetylgalactosamine residue at threonine 106 modifies the dynamics and structure of interferon α2a around the glycosylation site. J. Biol. Chem. 288, 247–254
17. Kabat, E. A., Wu, T. T., Perry, H. M., Gottesman, K. S., and Foeller (1991) Sequences of Proteins of Immunological Interest. U.S. Public Health Service, National Institutes of Health, Washington, D. C.
18. Oganessian, V., Damschroder, M. M., Cook, K. E., Wu, H., and D’Acqua, W. F. (2009) Crystallization and preliminary x-ray diffraction analysis of the complex between a human anti-interferon antibody fragment and human interferon α-2A. Acta Crystallogr. Sect. F Struct. Biol. Crystal. Commun. 65, 14–16
19. Otwinowski, Z., and Minor, W. (1997) Methods Enzymol. 276, 307–326
20. Collaborative Computational Project, Number 4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760–763
21. Peng, L., Oganessian, V., Wu, H., D’Acqua, W. F., and Damschroder, M. M. (2015) Molecular basis for the antagonistic activity of an anti-interferon α receptor 1 antibody. MAbs 7, 428–439
22. McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C., and Read, R. J. (2005) Likelihood-enhanced fast translation functions. Acta Crystallogr. D Biol. Crystallogr. 61, 458–464
23. Vagin, A., and Teplyakov, A. J. (1997) MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 30, 1022–1025
24. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., and Bourne, P. E. (2000) The Protein Data Bank. Nucleic Acids Res. 28, 235–242
25. Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47, 110–119
26. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of
macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240–255
27. Painter, J., and Merritt, E. A. (2006) Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. D Biol. Crystallogr. 62, 439–450
28. Painter, J., and Merritt, E. A. (2006) TLSMD web server for the generation of multi-group TLS models. J. Appl. Crystallogr. 39, 109–111
29. Stanfield, R. L., Zemla, A., Wilson, I. A., and Rupp, B. (2006) Antibody elbow angles are influenced by their light chain class. J. Mol. Biol. 357, 1566–1574
30. Uzé, G., Lutfalla, G., and Gresser, I. (1990) Genetic transfer of a functional human interferon α receptor into mouse cells: cloning and expression of its cDNA. Cell 60, 225–234
31. Novick, D., Cohen, B., and Rubinstein, M. (1994) The human interferon α/β receptor: characterization and molecular cloning. Cell 77, 391–400
32. Gavutis, M., Lata, S., Lamken, P., Müller, P., and Piehler, J. (2005) Lateral ligand-receptor interactions on membranes probed by simultaneous fluorescence-interference detection. Biophys. J. 88, 4289–4302
33. Roisman, L. C., Jaitin, D. A., Baker, D. P., and Schreiber, G. (2005) Mutational analysis of the IFNAR1 binding site on IFN-α2 reveals the architecture of a weak ligand-receptor binding-site. J. Mol. Biol. 353, 271–281
34. Lamken, P., Lata, S., Gavutis, M., and Piehler, J. (2004) Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers. J. Mol. Biol. 341, 303–318
35. Lewerenz, M., Mogensen, K. E., and Uzé, G. (1998) Shared receptor components but distinct complexes for α and β interferons. J. Mol. Biol. 282, 585–599
36. Chuntharapai, A., Gibbs, V., Lu, J., Ow, A., Marsters, S., Ashkenazi, A., DeVos, A., and Jin Kim, K. (1999) Determination of residues involved in ligand binding and signal transmission in the human IFN-α receptor 2. J. Immunol. 163, 766–773
37. Piehler, J., Roisman, L. C., and Schreiber, G. (2000) New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface. J. Biol. Chem. 275, 40425–40433
38. Chill, J. H., Nivasch, R., Levy, R., Albeck, S., Schreiber, G., and Anglister, J. (2002) The human interferon receptor: NMR-based modeling, mapping of the IFN-α2 binding site, and observed ligand-induced tightening. Biochemistry 41, 3575–3585
39. Quadt-Akabayov, S. R., Chill, J. H., Levy, R., Kessler, N., and Anglister, J. (2006) Determination of the human type I interferon receptor binding site on human interferon-α2 by cross saturation and an NMR-based model of the complex. Protein Sci. 15, 2656–2668
40. Thomas, C., Moraga, I., Levin, D., Krutzik, P. O., Podoplelova, Y., Trejo, A., Lee, C., Yarden, G., Vleck, S. E., Glenn, J. S., Nolan, G. P., Piehler, J., Schreiber, G., and Garcia, K. C. (2011) Structural linkage between ligand discrimination and receptor activation by type 1 interferons. Cell 146, 621–632
41. Cajean-Feroldi, C., Nosal, F., Nardeux, P. C., Gallet, X., Guymarho, J., Baycheler, F., Sempé, P., Tovey, M. G., Escary, J. L., and Eid, P. (2004) Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity. Biochemistry 43, 12498–12512
42. Kumaran, J., Wei, L., Kotra, I. P., and Fish, E. N. (2007) A structural basis for interferon-α-receptor interactions. FASEB J. 21, 3288–3296
43. Pan, M., Kalia, E., Scaglione, B. J., Raveche, E. S., Schreiber, G., and Langer, J. A. (2008) Mutation of the IFNAR-1 receptor binding site of human IFN-α2 generates type I IFN competitive antagonists. Biochemistry 47, 12018–12027
44. Kabash, W. A. (1976) Solution for the best rotation to relate two sets of vectors. Acta Crystallogr. Sect. A 32, 922–923
45. Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26, 283–291